Gadocoletic Acid

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 45 Experts worldwide ranked by ideXlab platform

Friedrich M. Cavagna - One of the best experts on this subject based on the ideXlab platform.

  • Detection of coronary stenoses with contrast enhanced, three-dimensional free breathing coronary MR angiography using the gadolinium-based intravascular contrast agent Gadocoletic Acid (B-22956).
    Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2006
    Co-Authors: Ingo Paetsch, Cosima Jahnke, Joerg Barkhausen, Elmar Spuentrup, Friedrich M. Cavagna, Bernhard Schnackenburg, Michael E. Huber, Matthias Stuber, Eckart Fleck, Eike Nagel
    Abstract:

    Purpose: To determine the diagnostic value of the intravascular contrast agent Gadocoletic Acid (B-22956) in three-dimensional, free breathing coronary magnetic resonance angiography (MRA) for stenosis detection in patients with suspected or known coronary artery disease. Methods: Eighteen patients underwent three-dimensional, free breathing coronary MRA of the left and right coronary system before and after intravenous application of a single dose of Gadocoletic Acid (B-22956) using three different dose regimens (group A 0.050 mmol/kg; group B 0.075 mmol/kg; group C 0.100 mmol/kg). Precontrast scanning followed a coronary MRA standard non-contrast T2 preparation/turbo-gradient echo sequence (T2Prep); for postcontrast scanning an inversion-recovery gradient echo sequence was used (real-time navigator correction for both scans). In pre- and postcontrast scans quantitative analysis of coronary MRA data was performed to determine the number of visible side branches, vessel length and vessel sharpness of each...

  • Gadocoletic Acid trisodium salt b22956 1 a new blood pool magnetic resonance contrast agent with application in coronary angiography
    Investigative Radiology, 2006
    Co-Authors: Pier Lucio Anelli, Vito Lorusso, Alberto Morisetti, Fabio Maggioni, Jie Zheng, Fulvio Uggeri, Friedrich M. Cavagna
    Abstract:

    Rationale and Objectives:Inversion recovery, three-dimensional, gradient-recalled echo magnetic resonance coronary angiography (IR-3D-GRE-MRCA), performed after administration of an intravascular T1-relaxing agent with prolonged permanence in the blood, is one of the most promising approaches to non

  • Gadocoletic Acid trisodium salt (b22956/1): a new blood pool magnetic resonance contrast agent with application in coronary angiography.
    Investigative radiology, 2006
    Co-Authors: Pier Lucio Anelli, Vito Lorusso, Alberto Morisetti, Fabio Maggioni, Jie Zheng, Fulvio Uggeri, Friedrich M. Cavagna
    Abstract:

    Rationale and Objectives:Inversion recovery, three-dimensional, gradient-recalled echo magnetic resonance coronary angiography (IR-3D-GRE-MRCA), performed after administration of an intravascular T1-relaxing agent with prolonged permanence in the blood, is one of the most promising approaches to non

  • Single-session magnetic resonance coronary angiography and myocardial perfusion imaging using the new blood pool compound B-22956 (Gadocoletic Acid): initial experience in a porcine model of coronary artery disease.
    Investigative radiology, 2005
    Co-Authors: Jie Zheng, Fabio Maggioni, Dana R. Abendschein, Orlando P. Simonetti, Gerhard Laub, J. Paul Finn, Robert J. Gropler, Friedrich M. Cavagna
    Abstract:

    Objective: The objective of this study was to evaluate a new blood pool contrast agent, B-22956, for detecting myocardial perfusion abnormality and coronary artery stenosis by magnetic resonance imaging (MRI) in 1 setting. Materials and Methods: Coronary artery atherosclerotic stenoses were created in 6 miniswine. Myocardial first-pass perfusion imaging was performed with a bolus injection of 0.015 mmol/kg B-22956 during pharmacologic stress followed by postcontrast coronary artery imaging after another injection of B-22956/1. The total doses for the 6 pigs were 0.1 mmol/kg (n = 3) and 0.15 mmol/kg (n = 3). Perfusion upslope maps were analyzed and MR coronary artery images were reviewed by 2 readers. Results: For all 6 pigs, the normalized upslopes of the perfusion curves were 0.83 ± 0.12, 0.74 ± 0.15, and 0.52 ± 0.05 (P 75%), respectively. Mean signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) in right coronary artery images improved 90% and 200%, respectively, with a total dose of 0.1 mmol/kg of B-22956. Excellent agreements (kappa = 0.82) were achieved for evaluating the grade of stenosis between MR postcontrast coronary artery images and histopathology by 2 reviewers. Conclusion: The MR blood pool contrast agent B-22956 demonstrated the ability for detecting myocardial perfusion abnormalities and coronary artery stenosis in 1 setting.

  • Improved three-dimensional free-breathing coronary magnetic resonance angiography using Gadocoletic Acid (B-22956) for intravascular contrast enhancement.
    Journal of magnetic resonance imaging : JMRI, 2004
    Co-Authors: Ingo Paetsch, Friedrich M. Cavagna, Bernhard Schnackenburg, Michael E. Huber, Matthias Stuber, Eckart Fleck, Axel Bornstedt, Peter Boesiger, Eike Nagel
    Abstract:

    Purpose To evaluate Gadocoletic Acid (B-22956), a gadolinium-based paramagnetic blood pool agent, for contrast-enhanced coronary magnetic resonance angiography (MRA) in a Phase I clinical trial, and to compare the findings with those obtained using a standard noncontrast T2 preparation sequence. Materials and Methods The left coronary system was imaged in 12 healthy volunteers before B-22956 application and 5 (N = 11) and 45 (N = 7) minutes after application of 0.075 mmol/kg of body weight (BW) of B-22956. Additionally, imaging of the right coronary system was performed 23 minutes after B-22956 application (N = 6). A three-dimensional gradient echo sequence with T2 preparation (precontrast) or inversion recovery (IR) pulse (postcontrast) with real-time navigator correction was used. Assessment of the left and right coronary systems was performed qualitatively (a 4-point visual score for image quality) and quantitatively in terms of signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), vessel sharpness, visible vessel length, maximal luminal diameter, and the number of visible side branches. Results Significant (P < 0.01) increases in SNR (+42%) and CNR (+86%) were noted five minutes after B-22956 application, compared to precontrast T2 preparation values. A significant increase in CNR (+40%, P < 0.05) was also noted 45 minutes postcontrast. Vessels (left anterior descending artery (LAD), left coronary circumflex (LCx), and right coronary artery (RCA)) were also significantly (P < 0.05) sharper on postcontrast images. Significant increases in vessel length were noted for the LAD (P < 0.05) and LCx and RCA (both P < 0.01), while significantly more side branches were noted for the LAD and RCA (both P < 0.05) when compared to precontrast T2 preparation values. Conclusion The use of the intravascular contrast agent B-22956 substantially improves both objective and subjective parameters of image quality on high-resolution three-dimensional coronary MRA. The increase in SNR, CNR, and vessel sharpness minimizes current limitations of coronary artery visualization with high-resolution coronary MRA. J. Magn. Reson. Imaging 2004;20:288–293. © 2004 Wiley-Liss, Inc.

Pier Lucio Anelli - One of the best experts on this subject based on the ideXlab platform.

  • molecular determinants in the transport of a bile Acid derived diagnostic agent in tumoral and nontumoral cell lines of human liver
    Journal of Pharmacology and Experimental Therapeutics, 2006
    Co-Authors: Antonin Libra, Cristina Fernetti, Vito Lorusso, Massimo Visigalli, Pier Lucio Anelli, Frantisek Staud, Claudio Tiribelli, Lorella Pascolo
    Abstract:

    Contrast-enhanced magnetic resonance imaging (CE-MRI) is a valuable technique for the diagnosis of liver diseases. As Gadocoletic Acid trisodium salt (B22956/1), a new contrast agent showing high biliary excretion, may be potentially advantageous in hepatobiliary imaging, the aim of the study was to investigate the molecular mechanisms of hepatic transport of the B22956 ion in a cellular model of hepatic tumor. B22956 ion uptake was measured in tumoral (HepG2) and nontumoral (Chang liver) hepatic cell lines. Absolute quantitative real-time reverse transcriptase (RT)-polymerase chain reaction (PCR) analyses, using cloned PCR products as standards, were performed on total RNA of both cell lines and normal liver to evaluate the transcription of 12 transport genes: SLCO1A2, SLCO2B1, SLCO1B1, SLCO3A1, SLCO4A1, SLCO1B3, SLC22A7, SLC22A8, SLC22A1, SLC10A1, SLC15A1, and SLC15A2. B22956 transport was more efficient in Chang liver than in HepG2 cells and was inhibited by cholecystokinin-8, a specific substrate of OATP1B3. Real-time RT-PCR analyses revealed different transcription profiles in the tumoral and nontumoral cell lines. Compared with normal liver, the expression of SLCO1B1, SLCO3A1, and SLCO1B3 was greatly repressed in HepG2 cells, whereas SLCO2B1, SLC22A7, and SLC22A8 expression was either maintained or increased. On the contrary, in Chang liver cells, SLC22A7 and SLC22A8 genes were undetectable, whereas the expression of SLCO3A1, SLCO4A1, and SLCO1B3 was similar to normal liver. Transport studies and gene expression analyses indicated that B22956 ion is a good substrate to the liver-specific OATP1B3, reported to be poorly expressed or absent in human liver tumors. Therefore, B22956 may be helpful in detecting hepatic neoplastic lesions by CE-MRI.

  • Gadocoletic Acid trisodium salt b22956 1 a new blood pool magnetic resonance contrast agent with application in coronary angiography
    Investigative Radiology, 2006
    Co-Authors: Pier Lucio Anelli, Vito Lorusso, Alberto Morisetti, Fabio Maggioni, Jie Zheng, Fulvio Uggeri, Friedrich M. Cavagna
    Abstract:

    Rationale and Objectives:Inversion recovery, three-dimensional, gradient-recalled echo magnetic resonance coronary angiography (IR-3D-GRE-MRCA), performed after administration of an intravascular T1-relaxing agent with prolonged permanence in the blood, is one of the most promising approaches to non

  • Gadocoletic Acid trisodium salt (b22956/1): a new blood pool magnetic resonance contrast agent with application in coronary angiography.
    Investigative radiology, 2006
    Co-Authors: Pier Lucio Anelli, Vito Lorusso, Alberto Morisetti, Fabio Maggioni, Jie Zheng, Fulvio Uggeri, Friedrich M. Cavagna
    Abstract:

    Rationale and Objectives:Inversion recovery, three-dimensional, gradient-recalled echo magnetic resonance coronary angiography (IR-3D-GRE-MRCA), performed after administration of an intravascular T1-relaxing agent with prolonged permanence in the blood, is one of the most promising approaches to non

  • Molecular determinants in the transport of a bile Acid derived diagnostic agent in tumoral and non-tumoral cell lines of human liver.
    2006
    Co-Authors: Libra A, Pier Lucio Anelli, Fernetti C, Visigalli M, Staud F, Tiribelli C, Pascolo L.
    Abstract:

    Contrast-enhanced magnetic resonance imaging (CE-MRI) is a valuable technique for the diagnosis of liver diseases. As Gadocoletic Acid trisodium salt (B22956/1), a new contrast agent showing high biliary excretion, may be potentially advantageous in hepatobiliary imaging, the aim of the study was to investigate the molecular mechanisms of hepatic transport of the B22956 ion in a cellular model of hepatic tumor. B22956 ion uptake was measured in tumoral (HepG2) and nontumoral (Chang liver) hepatic cell lines. Absolute quantitative real-time reverse transcriptase (RT)-polymerase chain reaction (PCR) analyses, using cloned PCR products as standards, were performed on total RNA of both cell lines and normal liver to evaluate the transcription of 12 transport genes: SLCO1A2, SLCO2B1, SLCO1B1, SLCO3A1, SLCO4A1, SLCO1B3, SLC22A7, SLC22A8, SLC22A1, SLC10A1, SLC15A1, and SLC15A2. B22956 transport was more efficient in Chang liver than in HepG2 cells and was inhibited by cholecystokinin-8, a specific substrate of OATP1B3. Real-time RT-PCR analyses revealed different transcription profiles in the tumoral and nontumoral cell lines. Compared with normal liver, the expression of SLCO1B1, SLCO3A1, and SLCO1B3 was greatly repressed in HepG2 cells, whereas SLCO2B1, SLC22A7, and SLC22A8 expression was either maintained or increased. On the contrary, in Chang liver cells, SLC22A7 and SLC22A8 genes were undetectable, whereas the expression of SLCO3A1, SLCO4A1, and SLCO1B3 was similar to normal liver. Transport studies and gene expression analyses indicated that B22956 ion is a good substrate to the liver-specific OATP1B3, reported to be poorly expressed or absent in human liver tumors. Therefore, B22956 may be helpful in detecting hepatic neoplastic lesions by CE-MRI

Vito Lorusso - One of the best experts on this subject based on the ideXlab platform.

  • Contrast-enhanced MRI of murine sponge model for progressive angiogenesis assessed with gadoteridol (ProHance) and Gadocoletic Acid trisodium salt (B22956/1).
    Journal of magnetic resonance imaging : JMRI, 2008
    Co-Authors: Simona Ramponi, Cristina Rebaudengo, Claudia Cabella, Adriana Grotti, Stefania Vultaggio, Silvio Aime, Alberto Morisetti, Vito Lorusso
    Abstract:

    Purpose To investigate the potential value of MRI for noninvasive assessment of angiogenesis in a murine model exploiting the properties of two contrast agents, gadoteridol (ProHance) and Gadocoletic Acid trisodium salt (B22956/1). Materials and Methods Biocompatible sponges were implanted in both mice flanks. Stimulated sponges contained human recombinant basic fibroblast growth factor (bFGF) as the angiogenic agent; control sponges contained vehicle. Angiogenesis was evaluated by MRI after injection of extravascular (ProHance) or blood-pool (B22956/1) contrast agents at different times after sponge implantation. Sponges signal intensity enhancement was calculated both as the relative enhancement and the rate of relative enhancement. Results from MRI were validated by classic biochemical (hemoglobin level and protein content) and morphological (histology) assays. Results The intrinsic different properties of ProHance and B22956/1 in wash-in and wash-out kinetics were useful to detect progressive vascularization and the establishment of a functional vascular network in the implants. Moreover, MRI allowed the appreciation of differences in neovessel colonization between bFGF-treated sponges and controls. Hemoglobin level, protein content, and histology confirmed the sponge vascularization and MRI results. Conclusion Contrast-enhanced MRI is a reliable tool to study vascular characteristics in animal models of angiogenesis. The different kinetic properties of contrast agents can provide evidence of different functional neovascularization aspects and levels. J. Magn. Reson. Imaging 2008;27:872–880. © 2008 Wiley-Liss, Inc.

  • molecular determinants in the transport of a bile Acid derived diagnostic agent in tumoral and nontumoral cell lines of human liver
    Journal of Pharmacology and Experimental Therapeutics, 2006
    Co-Authors: Antonin Libra, Cristina Fernetti, Vito Lorusso, Massimo Visigalli, Pier Lucio Anelli, Frantisek Staud, Claudio Tiribelli, Lorella Pascolo
    Abstract:

    Contrast-enhanced magnetic resonance imaging (CE-MRI) is a valuable technique for the diagnosis of liver diseases. As Gadocoletic Acid trisodium salt (B22956/1), a new contrast agent showing high biliary excretion, may be potentially advantageous in hepatobiliary imaging, the aim of the study was to investigate the molecular mechanisms of hepatic transport of the B22956 ion in a cellular model of hepatic tumor. B22956 ion uptake was measured in tumoral (HepG2) and nontumoral (Chang liver) hepatic cell lines. Absolute quantitative real-time reverse transcriptase (RT)-polymerase chain reaction (PCR) analyses, using cloned PCR products as standards, were performed on total RNA of both cell lines and normal liver to evaluate the transcription of 12 transport genes: SLCO1A2, SLCO2B1, SLCO1B1, SLCO3A1, SLCO4A1, SLCO1B3, SLC22A7, SLC22A8, SLC22A1, SLC10A1, SLC15A1, and SLC15A2. B22956 transport was more efficient in Chang liver than in HepG2 cells and was inhibited by cholecystokinin-8, a specific substrate of OATP1B3. Real-time RT-PCR analyses revealed different transcription profiles in the tumoral and nontumoral cell lines. Compared with normal liver, the expression of SLCO1B1, SLCO3A1, and SLCO1B3 was greatly repressed in HepG2 cells, whereas SLCO2B1, SLC22A7, and SLC22A8 expression was either maintained or increased. On the contrary, in Chang liver cells, SLC22A7 and SLC22A8 genes were undetectable, whereas the expression of SLCO3A1, SLCO4A1, and SLCO1B3 was similar to normal liver. Transport studies and gene expression analyses indicated that B22956 ion is a good substrate to the liver-specific OATP1B3, reported to be poorly expressed or absent in human liver tumors. Therefore, B22956 may be helpful in detecting hepatic neoplastic lesions by CE-MRI.

  • Gadocoletic Acid trisodium salt b22956 1 a new blood pool magnetic resonance contrast agent with application in coronary angiography
    Investigative Radiology, 2006
    Co-Authors: Pier Lucio Anelli, Vito Lorusso, Alberto Morisetti, Fabio Maggioni, Jie Zheng, Fulvio Uggeri, Friedrich M. Cavagna
    Abstract:

    Rationale and Objectives:Inversion recovery, three-dimensional, gradient-recalled echo magnetic resonance coronary angiography (IR-3D-GRE-MRCA), performed after administration of an intravascular T1-relaxing agent with prolonged permanence in the blood, is one of the most promising approaches to non

  • Feasibility evaluation of the application of Silicon Drift Detectors in studies of drug delivery in liver
    2006 IEEE Nuclear Science Symposium Conference Record, 2006
    Co-Authors: Roberto Alberti, Vito Lorusso, Lorella Pascolo, Carlo Fiorini, Chiara Guazzoni, T. Klatka, Antonio Longoni, Riccarda Delfino, Lisa Vaccari, Fulvia Arfelli
    Abstract:

    This work aims to assess the feasibility of studying the distribution of drugs and diagnostic agents in biological specimens by means of XRF detected with high-resolution and high sensitivity Silicon Drift Detectors. In the present study we have employed as diagnostic agent a gadolinium complex (Gadocoletic Acid trisodium salt - B22956/1). The primary excitation beam was the light of the SYRMEP beamline of the Elettra synchrotron light source. For calibration purposes we analyzed solutions of the Gd complex in water at different dilutions. The minimum level of Gd detected is 5 mug/ml. We measured the Gd complex distribution in different organs (liver, kidney, spleen, lung) and in blood of mice at different times after a single injection of B22956 (250 mg/Kg body weight) and the Gd complex uptake in human liver-derived cells. This technique will allow the measure of pharmacokinetics and the study of the homogeneity of drug distribution inside organs providing a new tool in the development, follow-up and tracking of drug delivery in vitro.

  • Gadocoletic Acid trisodium salt (b22956/1): a new blood pool magnetic resonance contrast agent with application in coronary angiography.
    Investigative radiology, 2006
    Co-Authors: Pier Lucio Anelli, Vito Lorusso, Alberto Morisetti, Fabio Maggioni, Jie Zheng, Fulvio Uggeri, Friedrich M. Cavagna
    Abstract:

    Rationale and Objectives:Inversion recovery, three-dimensional, gradient-recalled echo magnetic resonance coronary angiography (IR-3D-GRE-MRCA), performed after administration of an intravascular T1-relaxing agent with prolonged permanence in the blood, is one of the most promising approaches to non

Jie Zheng - One of the best experts on this subject based on the ideXlab platform.

Fabio Maggioni - One of the best experts on this subject based on the ideXlab platform.